Researchers have found a clue that which type of prostate tumor can return after surgery. This study was published in Proceedings of the National Academy of Sciences. The destructive properties of prostate cancer are attributed to the switching of a gene called as SPARCL1. Decline in the level of protein could increase the chances of recurrence of prostate cancer.
In America prostate cancer is the second leading cause of death in men. According to the American Cancer Society, it is estimated that almost 240,000 cases diagnosed per year in America. It was further observed that 40% of these cases can recur even after surgery as said by Edward Schaeffer, a study author. This research will facilitate the physicians to determine that in which patient prostate cancer could return.
“It’s very important to identify patients who are going to do really well after surgery, and maybe don’t need to worry so much about cancer recurrence,” said Schaeffer, an associate professor of urology and oncology at the Johns Hopkins University School of Medicine in Baltimore. “Those individuals who are at an increased risk may need closer follow up or more intensive interventions with treatments such as radiation.”
SPARCL1 gene switch of during the time of prostate formation to permit the prostate gland cell to grow but after puberty it produce the normal level of protein as said by Schaeffer.
Researchers have made a clear examination of DNA of prostate cancer of those patients in which prostate gland was removed surgically and they found that SPARCL1 gene is the possible culprit.
“Although this work focused on prostate cancer, our work also suggests that it may play a role regulating other cancer recurrences as well,” Schaeffer said. “Mechanisms that regulate SPARCL1s expression are key next steps so this molecular pathway can be modulated.”
Researchers are now working in designing a test that can measure SPARCL1 gene.
Copyright 2012 Medimoon.com. All rights reserved. No part of this site can be reproduced without our written permission.